Enzon Pharmaceuticals, Inc. has submitted an IND to the FDA for its HIF-1alpha (hypoxia-inducible factor 1alpha) antagonist, a highly visible, validated target in many cancer types, including solid tumors. “2006 was a very exciting year for Enzon, as we began to build an innovative oncology pipeline, said Jeffrey Buchalter, chairman and chief executive officer, Enzon. The filing of HIF-1alpha, our fourth IND submission in 2006, demonstrates our strong commitment to delivering on our p...